Literature DB >> 7027240

Multiple risk factor intervention trial (MRFIT).

J D Cohen, R H Grimm, W M Smith.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 7027240     DOI： 10.1016/0091-7435(81)90062-1

Source DB:  PubMed          Journal:  Prev Med        ISSN： 0091-7435            Impact factor:   4.018


× No keyword cloud information.
  7 in total

1.  Exercise in a behavioural weight control programme for obese patients with Type 2 (non-insulin-dependent) diabetes.

Authors:  R R Wing; L H Epstein; M Paternostro-Bayles; A Kriska; M P Nowalk; W Gooding
Journal:  Diabetologia       Date:  1988-12       Impact factor: 10.122

2.  Multiple risk factor intervention trial.

Authors:  M A Mishkel
Journal:  Can Med Assoc J       Date:  1983-05-15       Impact factor: 8.262

3.  Do type A men drink more frequently than type B men? Findings in the Multiple Risk Factor Intervention Trial (MRFIT).

Authors:  A R Folsom; J R Hughes; J F Buehler; M B Mittelmark; D R Jacobs; R H Grimm
Journal:  J Behav Med       Date:  1985-09

4.  Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial.

Authors:  Michael E Ernst; James D Neaton; Richard H Grimm; Gary Collins; William Thomas; Elsayed Z Soliman; Ronald J Prineas
Journal:  Hypertension       Date:  2011-10-24       Impact factor: 10.190

5.  Relationship between sialic acid and metabolic variables in Indian type 2 diabetic patients.

Authors:  Shivananda B Nayak; Geetha Bhaktha
Journal:  Lipids Health Dis       Date:  2005-08-10       Impact factor: 3.876

6.  The importance of cholesterol medication adherence: the need for behavioral change intervention programs.

Authors:  Hayden B Bosworth; Barbara Ngouyombo; Jan Liska; Leah L Zullig; Caroline Atlani; Anne C Beal
Journal:  Patient Prefer Adherence       Date:  2018-03-06       Impact factor: 2.711

7.  Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial.

Authors:  Jeremiah Stamler; James D Neaton; Jerome D Cohen; Jeffrey Cutler; Lynn Eberly; Gregory Grandits; Lewis H Kuller; Judith Ockene; Ronald Prineas
Journal:  J Am Heart Assoc       Date:  2012-10-25       Impact factor: 5.501
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.